EX-10.31 16 0016.txt AMENDMENT NO 1 TO G-CSF EUROPEAN LICENSE AGREEMENT Exhibit 10.31 ------------- AMENDMENT N0. 1 --------------- TO -- KIRIN-AMGEN, INC./AMGEN ----------------------- G-CSF EUROPEAN LICENSE AGREEMENT -------------------------------- THIS AMENDMENT N0. 1 ("Amendment No. 1") TO THAT CERTAIN KIRIN-AMGEN, INC./AMGEN G-CSF EUROPEAN LICENSE AGREEMENT ("License Agreement"), is made and entered into this 1st day of June, 1987, by and between AMGEN INC., a Delaware corporation ("Amgen"), and KIRIN-AMGEN, INC., a California corporation ("Corporation"). R E C I T A L S - - - - - - - - A. Amgen and Corporation have previously executed that certain License Agreement regarding G-CSF. B. The parties desire to incorporate certain definitional changes into the License Agreement. NOW, THEREFORE, it is agreed as follows: 1. Article I at pages 2-3 of the License Agreement is hereby amended as follows: "ARTICLE I DEFINITIONS ----------- 1.01 Incorporation by Reference. Unless otherwise defined -------------------------- herein, capitalized terms shall have the meanings specified in that certain Company Shareholders' Agreement dated May 11, 1984, as amended ("Shareholders' Agreement"), and in that certain Research, Development, Technology Disclosure and License Agreement: PPO effective as of July 1, 1985 ("PPO Agreement"). 1.04 G-CSF Products. "G-CSF Products" shall mean any -------------- product, method or system for human pharmaceutical use which contains G-CSF as its single primary element. 1.05 G-CSF Technology. "G-CSF Technology" shall mean all G- ---------------- CSF technical information whether tangible or intangible, including any and all data, pre-clinical and clinical results, techniques, discoveries, inventions, ideas, processes, know-how, patents, inventor's certificates, trade secrets and other proprietary information, and any physical, chemical or biological material (including cell lines) and any replication of any part of any such material. 1.08 G-CSF. "G-CSF" shall mean a glycosylated or ----- nonglycosylated molecule consisting of the linear array of amino acids attached as Exhibit "A" hereto or any variation thereof consisting of additions, deletions or substitutions of up to ten amino acids, and shall include the definition of PPO as set forth in the PPO Agreement." 2. Except to the extent as provided herein, the provisions of the License Agreement, as amended, are hereby ratified and confirmed in all respects. IN WITNESS WHEREOF, the undersigned have caused this Amendment No. 1 to be executed as of the first day written above . AMGEN INC., a Delaware corporation By /s/ George B. Rathmann ------------------------------------- George B. Rathmann, President "Amgen" KIRIN-AMGEN, INC., a California corporation By /s/ Y. Yamamoto ------------------------------------------ Yashushi Yamamoto, Chairman "Corporation" -2- G-CSF ------------ A Amino acids [23-30] Lys Ile Gln Gly Asp Gly Ala Ala mRNA AAG AUC CAG GGC GAU GGC GCA GCG Probes [24-23 mers] TTC TAC GTC CCT CTA CCT GGT CG B -12 -10 ELU TRP HIS SER ALA LEU TRP THR VAL GLN GLU ALA THR PRO LEU CIG TGG CAC AGI GIA CIC TGG ACR GIG CAG GAA GCC ACC CCC CIG 10 ALY PRO ALA SER SER LEU PRO GLN SER PHE LEU LEU LYS CYS LEU GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG TGC TTA 20 30 phe ALU GLN VAL ARG LYS ILE GLN GLY ASP GLY ALA ALA LEU GLN GLN GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG GAG gly LYS LEU CYS ALA THR TYR LYS LEU CYS HIS PRO GLU GLU LEU VAL AAG CTG TGT GCC ACC TAC AAG CTG TGT CAC CCC GAG GAG CTG GTG 50 60 LEU LEU GLY HIS SER LEU GLY ILE PRO TRP ALA PRO LEU SER SER CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC 70 CYS PRO SER GLN ALA LEU GLN LEU ALA GLY CYS LEU SER GLN LEU TGC CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC 80 90 HIS SER GLY LEU PHE LEU TYR GLN GLY LEU LEU GLN ALA LEU GLN CAT AGC GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA 100 GLY ILE SER PRO GLU LEU GLY PRO THR LEU ASP THR LEU GLN LEU GGG ATC TCC CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG 110 120 ASP VAL ALA ASP PHE ALA THR THR ILE TRP GLN GLN MET GLU GLU GAC GTC GCC GAC TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA 130 LEU GLY MET ALA PRO ALA LEU GLN PRO THR GLN GLY ALA MET PRO CTG GGA ATG GCC CCT GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG 140 150 ALA PHE ALA SER ALA PHE GLN ARG ARG ALA GLY GLY VAL LEU VAL GCC TTC GCC TCT GCT TTC CAG CGC CGG GCA GGA GGG GTC CTG GTT 160 ALA SER HIS LEU GLN SER PHE LEU GLU VAL SER TYR ARG VAL LEU GCC TCC CAT CTG CAG AGC TTC CTG GAG GTG TCG TAC CGC GTT CTA 170 174 ARG HIS LEU ALA GLN PRO OP CGC CAC CTT GCC CAG CCC TGA GCCAAGCCCTCCCCATCCCATGTATTTATCT CTATTTAATATTTATGTCTATTTAAGCCTCATATTTAAAGACAGGGAAGAGCAGAACGG AGCCCCAGGCCTCTGTGTCCTTCCCTGCATTTCTGAGTTTCATTCTCCTGCCTGTAGCA GTGAGAAAAAGCTCCTGTCCTCCCATCCCCTGGACTGGGAGGTAGATAGGTAAATACCA AGTATTTATTACTATGACTGCTCCCCAGCCCTGGCTCTGCAATGGGCACTGGGATGAGC CGCTGTGAGCCCCTGGTCCTGAGGGTCCCCACCTGGGACCCTTGAGAGTATCAGGTCTC CCACGTGGGAGACAAGAAATCCCTGTTTAATATTTAAACAGCAGTGTTCCCCATCTGGG TCCTTGCACCCCTCACTCTGGCCTCAGCCGACTGCACAGCGGCCCCTGCATCCCCTTGG CTGTGAGGCCCCTGGACAAGCAGAGGTGGCCAGAGCTGGGAGGCATGGCCCTGGGGTCC CACGAATTTGCTGGGGAATCTCGTTTTTCTTCTTAAGACTTTTGGGACATGGTTTGACT CCCGAACATCACCGACGTGTCTCCTGTTTTTCTGGGTGGCCTCGGGACACCTGCCCTGC CCCCACGAGGGTCAGGACTGTGACTCTTTTTAGGGCTAGGCAGGTGCCTGGACATTTGC CTTGCTGGACGGGGACTGGGGATGTGGGAGGGAGCAGACAGGAGGAATCATGTCAGGCC TGTGTGTGAAAGGAAGCTCCACTGTCACCCTCCACCTCTTCACCCCCCACTCACCAGTG TCCCCTCCACTGTCACATTGTAACTGAACTTCAGGATAATAAAGTGTTTGCCTCCAA EXHIBIT "A"